Sei Investments Co. Boosts Holdings in Harrow, Inc. $HROW

Sei Investments Co. raised its position in Harrow, Inc. (NASDAQ:HROW) by 119.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,032 shares of the company’s stock after acquiring an additional 20,706 shares during the period. Sei Investments Co. owned approximately 0.10% of Harrow worth $1,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Militia Capital Management LLC acquired a new position in shares of Harrow during the first quarter worth $829,000. First Trust Advisors LP boosted its position in shares of Harrow by 1.2% in the 1st quarter. First Trust Advisors LP now owns 154,096 shares of the company’s stock worth $5,433,000 after purchasing an additional 1,865 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after buying an additional 208,972 shares during the last quarter. KBC Group NV purchased a new position in Harrow during the 1st quarter worth $31,000. Finally, Blackhawk Capital Partners LLC increased its position in Harrow by 27.9% during the 1st quarter. Blackhawk Capital Partners LLC now owns 172,332 shares of the company’s stock valued at $6,076,000 after buying an additional 37,574 shares in the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

More Harrow News

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Harrow reported second-quarter revenue of approximately $70.7 million, up 10.9% year over year and slightly above the $70.35 million analyst estimate. Gross profit increased 6% to $50.4 million. Harrow Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management issued fiscal 2026 revenue guidance of $350 million to $365 million, above the roughly $348.8 million consensus forecast, suggesting confidence in continued commercial growth. Harrow earnings and guidance
• Positive Sentiment: BTIG reaffirmed its Buy rating and set a $63 price target, implying substantial upside from recent trading levels. The earnings call also emphasized record demand and strategic expansion. BTIG rating update
• Neutral Sentiment: The reported short-interest data showed zero shares and a zero-day days-to-cover ratio, but the stated month-over-month increase was listed as “NaN,” making the data unreliable and unlikely to provide a meaningful trading signal.
• Negative Sentiment: Harrow reported a quarterly loss of $0.34 per share, substantially worse than the $0.18 consensus estimate. Operating loss widened to $11.0 million, net loss attributable to common shareholders reached $17.3 million, and operating cash flow was negative $9.8 million. Harrow Q2 loss report
• Negative Sentiment: Profitability remains under pressure despite sales growth, while total liabilities rose to approximately $402 million. The earnings miss and heavier balance sheet appear to be the main reasons investors reacted negatively.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Monday, July 20th. Cantor Fitzgerald dropped their price target on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen downgraded shares of Harrow from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Harrow in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Harrow has an average rating of “Moderate Buy” and an average price target of $69.43.

Harrow Price Performance

Shares of HROW opened at $39.42 on Wednesday. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. The company’s fifty day moving average price is $40.60 and its 200-day moving average price is $39.96. Harrow, Inc. has a 1-year low of $28.54 and a 1-year high of $54.85. The firm has a market capitalization of $1.47 billion, a PE ratio of -39.42 and a beta of 0.28.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.16). Harrow had a negative return on equity of 31.83% and a negative net margin of 13.51%.The firm had revenue of $70.66 million during the quarter, compared to analysts’ expectations of $69.84 million. On average, equities research analysts predict that Harrow, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Harrow

In other news, Director Adrienne L. Graves acquired 1,000 shares of Harrow stock in a transaction dated Monday, May 18th. The stock was purchased at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the purchase, the director directly owned 1,000 shares in the company, valued at $31,070. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew R. Boll bought 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were purchased at an average cost of $29.90 per share, with a total value of $104,650.00. Following the acquisition, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at approximately $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 12.80% of the stock is currently owned by corporate insiders.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.